Earlier this year, we shared with you the decision by the Therapeutic Goods Administration (TGA) to allow psychiatrists who are specifically authorised under the Authorised Prescriber scheme, to access MDMA (the active ingredient in ecstasy) for post-traumatic stress disorder (PTSD) and psilocybin (a compound found in “magic mushrooms”) for treatment-resistant depression.
As we follow this news, we could likely see prescriptions for MDMA (for clinical and research purposes) as early as December. Vitura Health, a medicinal cannabis producer, announced they have now received bulk active ingredient MDMA and the manufacturing process to create finished dosages is currently underway.
It also seems that clinical and research prescriptions for psilocybin are not far away either, with the company expecting to receive bulk psilocybin products by the end of November.
To read the full article, click here.
As mentioned in our previous articles, the TGA’s limited approval of these psychedelic substances has implications for workplace drug and alcohol programs as it continues to add complexity into how medicinal and illicit drug use is interpreted and actioned.
It also reinforces the fact that in this ever-changing environment, it is becoming increasingly important to keep yourself, managers, and staff up to date with factual information from a reliable, expert source.
Our upcoming webinar on drug and alcohol trends is a perfect opportunity to do just that. To find out more or to register for the webinar below
DASA (Drug and Alcohol Solutions Australia) is proud to be leading the way in workplace drug and alcohol testing services throughout Australia. Whether your need is for workplace drug and workplace alcohol testing, advice on drug and alcohol policy or ideas on how to communicate your workplace expectations, policies and procedures to your staff, DASA can help. We have the experience, technical expertise and people to lead you to the right solution.
Comments